Form 4: Revolution Medicines' Chief Operating Officer Sells Shares to Cover Tax Obligations

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,329 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On December 16, 2024, Margaret Horn, the Chief Operating Officer of Revolution Medicines, sold 4,329 shares of the company's common stock.
• The sale was executed at a price of $45.4038 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following the transaction, Horn directly owns 127,991 shares, which includes 68,876 RSUs.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports a routine transaction related to insider stock sales for tax purposes. There is no indication of positive or negative implications for the company's performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Executives often sell shares to cover tax obligations or for personal financial planning. The Rule 10b5-1 plan is a common tool to avoid accusations of insider trading.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Revolution Medicines.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see similar filings from their executives related to stock sales for tax purposes or diversification strategies.
• The volume of shares sold and the timing align with typical patterns observed in insider transactions related to RSU vesting.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, as it is a routine sale of shares by an executive for tax purposes.
• Employees may be indirectly affected if such transactions influence overall market perception, but the impact is expected to be minimal.

Key Dates